Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY22 results · Apr–Jun 2021
Aarti Drugs reported revenue from operations of ₹579.95 crore (up 6.5% from Q1 FY21) and net profit of ₹48.81 crore (down 42.9% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 579.95 | 544.67 | +6.5% | 501.75 | +15.6% |
| Other income | 1.62 | 1.26 | +28.6% | 0.97 | +67.0% |
| Total income | 581.57 | 545.93 | +6.5% | 502.72 | +15.7% |
| Profit before tax | 64.68 | 116.28 | −44.4% | 65.25 | −0.9% |
| Net profit for the period | 48.81 | 85.45 | −42.9% | 51.65 | −5.5% |
| EPS, basic (₹) | 5.25 | 36.67 | not comparable | 5.54 | −5.2% |
| Net margin (%) | 8.4 | 15.7 | 10.3 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 505.79 | 475.55 | +6.4% | 452.08 | +11.9% |
| Other income | 1.64 | 1.24 | +32.3% | 0.85 | +92.9% |
| Total income | 507.43 | 476.79 | +6.4% | 452.93 | +12.0% |
| Profit before tax | 60.04 | 99.03 | −39.4% | 63.24 | −5.1% |
| Net profit for the period | 45.54 | 73.03 | −37.6% | 50.24 | −9.4% |
| EPS, basic (₹) | 4.90 | 31.34 | not comparable | 5.39 | −9.1% |
| Net margin (%) | 9.0 | 15.4 | 11.1 |
Consolidated
- Filed with BSE
- 28 Jul 2021, 15:11 IST
- Board meeting
- 27 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2021, 15:11 IST
- Board meeting
- 27 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Audited
- Source
- XBRL filing on BSE